Key insider transactions
Paul A. Mahon, who serves as Executive Vice President and General Counsel at United Therapeutics (NASDAQ:UTHR), carried out both a sale and a purchase of company stock on April 16, 2026. On that date Mahon sold 8,300 shares of common stock at prices that ranged from $574.034 to $578.2099, generating proceeds totaling approximately $4.78 million.
At the same time, Mahon acquired 8,300 shares through the exercise of stock options at an exercise price of $146.03 per share, for a total value of $1212049. Both the sale and the option exercise were executed pursuant to a pre-arranged 10b5-1 trading plan that was established on August 11, 2025.
Post-transaction ownership
After completing the sale and option exercise, Mahon directly owns 45,172 shares of United Therapeutics.
Valuation context and market analysis
According to InvestingPro analysis cited alongside the transactions, United Therapeutics currently trades above its Fair Value, placing it among overvalued equities. The report notes that investors can access detailed valuation metrics and 12 additional ProTips for UTHR through the comprehensive Pro Research Report.
Company developments cited alongside the insider activity
Several corporate and clinical updates were noted in parallel with the disclosure of Mahon’s transactions. The U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to miroliverELAP, an investigational liver assist product developed by Miromatrix Medical Inc. The device is intended to provide temporary liver support for patients with acute liver failure.
On the commercial and clinical front for United Therapeutics’ own portfolio, multiple brokerages adjusted their price targets for the company following positive trial data for Tyvaso in idiopathic pulmonary fibrosis (IPF). H.C. Wainwright raised its price target to $660, citing robust TETON-1 trial data that support Tyvaso’s potential expansion into IPF treatment. Jefferies increased its target to $733 and raised the probability of success for the IPF indication to 95%. BofA Securities adjusted its price target to $626 on the back of positive Phase 3 TETON-1 results. Raymond James initiated coverage with an Outperform rating and set a price target of $700, citing the potential for Tyvaso to capture significant sales.
What the filings show
The transactions disclosed in the filings reflect activity conducted under an established trading plan, and the combination of sale and option exercise left Mahon with a specific stated holding. The filings do not provide further commentary from the insider or company beyond the numerical and procedural details already disclosed.
Conclusion
The April 16 transactions by United Therapeutics’ executive combine a planned disposition with a simultaneous option exercise and were undertaken under a 10b5-1 plan put in place the prior year. They occurred amid notable regulatory and analyst developments for the company, and InvestingPro’s valuation commentary highlights that the stock was trading above its Fair Value at the time of the report.